Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial - Top-Institutions - MDSpire

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • By

  • Mengyao Liu

  • Zengjun Liu

  • Jing Xu

  • Xin Xu

  • Qibing Wu

  • Dongyuan Zhu

  • June 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Shandong Cancer Hospital
    Shandong Cancer Hospital

    Jinan, Shandong

    Key Differentiators

    • Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #4

    IRCCS San Raffaele Hospital
    IRCCS San Raffaele Hospital

    Milan, Lombardy

    Key Differentiators

    • Oncology

  • #5

    Tisch Cancer Institute
    Tisch Cancer Institute

    New York, New York

    Key Differentiators

    • Oncology

Original Source(s)

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial

  • by Mengyao Liu, Zengjun Liu, Jing Xu, Xin Xu, Qibing Wu, Dongyuan Zhu

  • June 8, 2026

Related Content

Knowledge, attitudes, and practices toward chemotherapy resistance among oncologists: a multinational cross-sectional study

Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential

NAT10 as a central node in cancer biology: integrating epitranscriptomic regulation, metabolic reprogramming, and immune modulation